Annual report pursuant to Section 13 and 15(d)

Basis of Presentation - Additional Information (Detail)

Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Sep. 22, 2022
Jun. 30, 2022
Apr. 28, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Basis Of Presentation [Line Items]            
Loss from operations       $ 25,338 $ 16,431 $ 18,536
Working capital       11,200 35,500  
Cash and cash equivalents       4,181 29,972  
Net accounts receivable       5,841 4,238  
Net cash and cash equivalents used in operating activities       (26,761) (16,710) (12,795)
Net cash and cash equivalents used in investing activities       3,727 707 96
Proceeds from the sale of common stock   $ 5,600   5,602 14,420 $ 6,912
Prepaid expenses and other current assets       $ 3,053 $ 2,012  
Basis Of Presentation [Line Items]            
Business Acquisitions, Purchase Price Allocation, Year of Acquisition, Description the Company acquired all of the issued and outstanding membership interests of Med-Fiber on the terms and subject to the conditions set forth in the Purchase Agreement, for a purchase price equal to $1,320,000, plus, subject to the satisfaction of certain milestones, additional earn-out consideration in an aggregate amount of up to $880,000. Med-Fiber was engaged in the business of manufacturing and supplying infrared transmitting fiber optics for laser power delivery applications and activities related thereto. The purchase was accounted for as an asset acquisition as substantially all of the fair value of the gross assets acquired is concentrated in a group of similar assets. The $2,220,000 is included as a component of property, plant, and equipment in the consolidated balance sheet as of December 31, 2022.          
BIOLASE stockholders [Member]            
Basis Of Presentation [Line Items]            
Reverse Stock Split     all common stock share numbers, share price amounts (including exercise prices, conversion prices, and closing market prices), and the common stock quantities issuable upon the exercise of warrants issued prior to April 28, 2022 contained in the consolidated financial statements and notes thereto reflect the one-for-twenty-five (1:25) reverse stock split a reverse stock split of BIOLASE common stock, at a ratio ranging from one-for-two (1:2) to one-for-twenty-five (1:25), with the final ratio to be determined by the Board. Immediately after the 2022 Annual Meeting, the Board approved a one-for-twenty-five (1:25) reverse stock split of the outstanding shares of BIOLASE common stock (the “Reverse Stock Split”).    
Cyber Incident            
Basis Of Presentation [Line Items]            
Prepaid expenses and other current assets       $ 400    
Private Placement [Member]            
Basis Of Presentation [Line Items]            
Proceeds from issuance of equity securities       5,600    
SWK Loan            
Basis Of Presentation [Line Items]            
Proceed from term loan offering       $ 1,000